vs
アジレント・テクノロジー（A）とEncompass Health Corp（EHC）の財務データ比較。上の社名をクリックして会社を切り替えられます
アジレント・テクノロジーの直近四半期売上が大きい（$1.8B vs $1.5B、Encompass Health Corpの約1.2倍）。アジレント・テクノロジーの純利益率が高く（17.0% vs 9.5%、差は7.5%）。Encompass Health Corpの前年同期比売上増加率が高い（9.9% vs 7.0%）。アジレント・テクノロジーの直近四半期フリーキャッシュフローが多い（$175.0M vs $116.7M）。過去8四半期でEncompass Health Corpの売上複合成長率が高い（8.3% vs 6.9%）
アジレント・テクノロジーはライフサイエンス、診断、応用化学分野向けのソリューションを世界中で提供する企業です。ライフサイエンス・応用市場部門は液体クロマトグラフィーシステム、質量分析計、ガスクロマトグラフィー、誘導結合プラズマ質量分析装置、原子吸光光度計などの分析機器を展開しています。
エンコンパスヘルスコーポレーション（旧Amcare、HealthSouth）は米国アラバマ州バーミンガムに本社を置く米国最大の入院リハビリサービス事業者で、39州とプエルトリコに173の入院リハビリ病院を展開し、脳卒中や神経疾患、心肺疾患、脳損傷から回復中の患者に専門的な治療とケアを提供している。
A vs EHC — 直接比較
損益計算書 — Q1 2026 vs Q4 2025
| 指標 | | |
|---|---|---|
| 売上 | $1.8B | $1.5B |
| 純利益 | $305.0M | $146.1M |
| 粗利率 | 52.6% | — |
| 営業利益率 | 19.6% | 16.7% |
| 純利益率 | 17.0% | 9.5% |
| 売上前年比 | 7.0% | 9.9% |
| 純利益前年比 | -4.1% | 20.8% |
| EPS（希薄化後） | $1.07 | $1.43 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $1.5B | ||
| Q3 25 | $1.7B | $1.5B | ||
| Q2 25 | $1.7B | $1.5B | ||
| Q1 25 | $1.7B | $1.5B | ||
| Q4 24 | $1.7B | $1.4B | ||
| Q3 24 | $1.6B | $1.4B | ||
| Q2 24 | $1.6B | $1.3B |
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $146.1M | ||
| Q3 25 | $336.0M | $126.5M | ||
| Q2 25 | $215.0M | $142.1M | ||
| Q1 25 | $318.0M | $151.5M | ||
| Q4 24 | $351.0M | $120.9M | ||
| Q3 24 | $282.0M | $108.2M | ||
| Q2 24 | $308.0M | $114.1M |
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | — | ||
| Q3 25 | 51.1% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 53.5% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 54.4% | — |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | 16.7% | ||
| Q3 25 | 20.7% | 14.9% | ||
| Q2 25 | 18.0% | 16.2% | ||
| Q1 25 | 22.4% | 16.4% | ||
| Q4 24 | 24.0% | 14.3% | ||
| Q3 24 | 21.1% | 13.6% | ||
| Q2 24 | 23.1% | 14.3% |
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | 9.5% | ||
| Q3 25 | 19.3% | 8.6% | ||
| Q2 25 | 12.9% | 9.7% | ||
| Q1 25 | 18.9% | 10.4% | ||
| Q4 24 | 20.6% | 8.6% | ||
| Q3 24 | 17.9% | 8.0% | ||
| Q2 24 | 19.6% | 8.8% |
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $1.43 | ||
| Q3 25 | $1.18 | $1.24 | ||
| Q2 25 | $0.75 | $1.39 | ||
| Q1 25 | $1.11 | $1.48 | ||
| Q4 24 | $1.23 | $1.18 | ||
| Q3 24 | $0.97 | $1.06 | ||
| Q2 24 | $1.05 | $1.12 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $1.8B | $72.2M |
| 総負債低いほど良い | $3.0B | $2.4B |
| 株主資本純資産 | $6.9B | $2.4B |
| 総資産 | $12.8B | $7.1B |
| 負債/資本比率低いほどレバレッジが低い | 0.44× | 1.00× |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $72.2M | ||
| Q3 25 | $1.5B | $48.7M | ||
| Q2 25 | $1.5B | $99.1M | ||
| Q1 25 | $1.5B | $95.8M | ||
| Q4 24 | $1.3B | $85.4M | ||
| Q3 24 | $1.8B | $147.8M | ||
| Q2 24 | $1.7B | $154.4M |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $2.4B | ||
| Q3 25 | $3.4B | $2.4B | ||
| Q2 25 | $3.3B | $2.3B | ||
| Q1 25 | $3.3B | $2.3B | ||
| Q4 24 | $3.3B | $2.4B | ||
| Q3 24 | $2.1B | $2.3B | ||
| Q2 24 | $2.1B | $2.7B |
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $2.4B | ||
| Q3 25 | $6.4B | $2.4B | ||
| Q2 25 | $6.1B | $2.3B | ||
| Q1 25 | $6.0B | $2.2B | ||
| Q4 24 | $5.9B | $2.1B | ||
| Q3 24 | $5.9B | $2.0B | ||
| Q2 24 | $6.2B | $1.8B |
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $7.1B | ||
| Q3 25 | $12.2B | $6.9B | ||
| Q2 25 | $12.2B | $6.8B | ||
| Q1 25 | $11.9B | $6.6B | ||
| Q4 24 | $11.8B | $6.5B | ||
| Q3 24 | $11.0B | $6.5B | ||
| Q2 24 | $10.9B | $6.4B |
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | 1.00× | ||
| Q3 25 | 0.53× | 1.01× | ||
| Q2 25 | 0.55× | 1.02× | ||
| Q1 25 | 0.56× | 1.08× | ||
| Q4 24 | 0.57× | 1.14× | ||
| Q3 24 | 0.36× | 1.20× | ||
| Q2 24 | 0.34× | 1.46× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $268.0M | $346.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $175.0M | $116.7M |
| FCFマージンFCF / 売上 | 9.7% | 7.6% |
| 設備投資強度設備投資 / 売上 | 5.2% | 14.8% |
| キャッシュ転換率営業CF / 純利益 | 0.88× | 2.37× |
| 直近12ヶ月FCF直近4四半期 | $993.0M | $439.2M |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $346.0M | ||
| Q3 25 | $362.0M | $270.8M | ||
| Q2 25 | $221.0M | $270.2M | ||
| Q1 25 | $431.0M | $288.6M | ||
| Q4 24 | $481.0M | $278.8M | ||
| Q3 24 | $452.0M | $267.8M | ||
| Q2 24 | $333.0M | $217.4M |
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $116.7M | ||
| Q3 25 | $259.0M | $83.7M | ||
| Q2 25 | $107.0M | $113.3M | ||
| Q1 25 | $334.0M | $125.5M | ||
| Q4 24 | $388.0M | $80.1M | ||
| Q3 24 | $360.0M | $120.3M | ||
| Q2 24 | $230.0M | $60.5M |
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | 7.6% | ||
| Q3 25 | 14.9% | 5.7% | ||
| Q2 25 | 6.4% | 7.8% | ||
| Q1 25 | 19.9% | 8.6% | ||
| Q4 24 | 22.8% | 5.7% | ||
| Q3 24 | 22.8% | 8.9% | ||
| Q2 24 | 14.6% | 4.6% |
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 14.8% | ||
| Q3 25 | 5.9% | 12.7% | ||
| Q2 25 | 6.8% | 10.8% | ||
| Q1 25 | 5.8% | 11.2% | ||
| Q4 24 | 5.5% | 14.1% | ||
| Q3 24 | 5.8% | 10.9% | ||
| Q2 24 | 6.5% | 12.1% |
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | 2.37× | ||
| Q3 25 | 1.08× | 2.14× | ||
| Q2 25 | 1.03× | 1.90× | ||
| Q1 25 | 1.36× | 1.90× | ||
| Q4 24 | 1.37× | 2.31× | ||
| Q3 24 | 1.60× | 2.48× | ||
| Q2 24 | 1.08× | 1.91× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
EHC
| Medicare | $1.0B | 66% |
| Medicare Advantage | $243.1M | 16% |
| Managed Care | $160.7M | 10% |
| Medicaid | $47.0M | 3% |
| Other Income Source | $44.8M | 3% |
| Other Thirdparty Payors | $11.2M | 1% |
| Workers Compensation | $7.6M | 0% |
| Patients | $4.6M | 0% |
